Who Paid My Doc
Jeffrey Spier
El Paso, TX Medical Doctor
NPI 1033222906 CMS profile 183403
7420 Remcon Cir, Bldg A, El Paso, TX 79912
General payments
$77,220
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$7,920
Through program year 2025, Jeffrey Spier of El Paso, TX is reported in the CMS Open Payments database as having received $77,220 across 572 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,920 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $29,269 | 164 | |
| 2024 | General | $23,593 | 171 | |
| 2023 | General | $6,010 | 66 | |
| 2022 | General | $1,315 | 38 | |
| 2021 | General | $7,779 | 39 | |
| 2020 | General | $3,907 | 17 | |
| 2019 | General | $5,346 | 77 |
Beside peers
- Jeffrey Spier
- Texas median
- Middle half of Texas
- National median
In program year 2025, general payments to Jeffrey Spier were reported at $29,269. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.
Show as a table
| Year | Jeffrey Spier | Texas median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,346 | $191 | $56–$744 | $163 |
| 2020 | $3,907 | $125 | $38–$452 | $114 |
| 2021 | $7,779 | $150 | $43–$543 | $132 |
| 2022 | $1,315 | $169 | $50–$606 | $149 |
| 2023 | $6,010 | $183 | $53–$639 | $160 |
| 2024 | $23,593 | $188 | $55–$666 | $164 |
| 2025 | $29,269 | $188 | $55–$669 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
3,379
Drug cost
$10,117,556
Branded share of claims
43.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Erleada Apalutamide | Brand | 350 | $5,209,986 | |
| Xtandi Enzalutamide | Brand | 154 | $2,196,041 | |
| Nubeqa Darolutamide | Brand | 144 | $1,913,765 | |
| Orgovyx Relugolix | Brand | 229 | $595,101 | |
| Myrbetriq Mirabegron | Brand | 85 | $87,293 | |
| Abiraterone Acetate | Generic | 60 | $63,574 | |
| Tamsulosin Hcl | Generic | 792 | $13,493 | |
| Mirabegron Er Mirabegron | Brand | 14 | $10,220 | |
| Solifenacin Succinate | Generic | 150 | $7,470 | |
| Finasteride | Generic | 330 | $4,242 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 88 billing codesPaid by Medicare
$621,585
Medicare patients
749
Services billed
11,431
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 44% | |
| Diabetes | 38% | |
| Cancer | 33% | |
| Ischemic heart disease | 32% | |
| Chronic kidney disease | 29% | |
| Atrial fibrillation | 19% | |
| Depression | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 35 | 5,820 | $120,970 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 26 | 180 | $25,528 |
| Injection, garamycin, gentamicin, up to 80 mg J1580 | Office | 19 | 28 | $42 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 19 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ERLEADA |
|
$484 | 350 | — |
| PROVENGE |
|
$429 | — | — |
| XTANDI |
|
$321 | 154 | — |
| LYNPARZA |
|
$228 | — | — |
| Nubeqa |
|
$150 | 144 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 19 in the dashboard with a free accountRecords
572 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.